Taking a new approach to tackle neurodegenerative diseases
Drug Discovery World
OCTOBER 4, 2022
William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . Diseases such as PSP and FTD have no licensed and available treatments. With its recent award of $3.35
Let's personalize your content